Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or…

By T. Witzig, L. Gordon, F. Cabanillas, M. Czuczman, C. Emmanouilides, R. Joyce, B. Pohlman, N. Bartlett, G. Wiseman, Norman M. Padre and 3 more. Journal of Clinical Oncology, 2002

1,157 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/3585b690c4910d9d1adf4e71f2fec66c0e90d974

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Golan
2. Quentin J. Baca
3. B. Leader

Citations in the corpus

• Protein therapeutics: a summary and pharmacological classification (2008, background): “Similarly, refractory CD20-positive non-Hodgkin's lymphoma cells can be destroyed selectively by ibritumomab tiuxetan, a monoclonal antibody that is directed against CD20 and linked to a radioactive yttrium isotope (Y-90”